CA3158321A1 - Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies - Google Patents
Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignanciesInfo
- Publication number
- CA3158321A1 CA3158321A1 CA3158321A CA3158321A CA3158321A1 CA 3158321 A1 CA3158321 A1 CA 3158321A1 CA 3158321 A CA3158321 A CA 3158321A CA 3158321 A CA3158321 A CA 3158321A CA 3158321 A1 CA3158321 A1 CA 3158321A1
- Authority
- CA
- Canada
- Prior art keywords
- capivasertib
- acalabrutinib
- administered
- pharmaceutically acceptable
- cell lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962930208P | 2019-11-04 | 2019-11-04 | |
| US62/930,208 | 2019-11-04 | ||
| PCT/EP2020/080493 WO2021089419A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3158321A1 true CA3158321A1 (en) | 2021-05-14 |
Family
ID=73043259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3158321A Pending CA3158321A1 (en) | 2019-11-04 | 2020-10-30 | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220401442A1 (enExample) |
| EP (1) | EP4054582B1 (enExample) |
| JP (1) | JP7575454B2 (enExample) |
| KR (1) | KR20220098175A (enExample) |
| CN (1) | CN114728003B (enExample) |
| AU (1) | AU2020381240C1 (enExample) |
| CA (1) | CA3158321A1 (enExample) |
| DK (1) | DK4054582T3 (enExample) |
| ES (1) | ES3055126T3 (enExample) |
| FI (1) | FI4054582T3 (enExample) |
| MX (1) | MX2022005250A (enExample) |
| PL (1) | PL4054582T3 (enExample) |
| PT (1) | PT4054582T (enExample) |
| WO (1) | WO2021089419A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230286A2 (en) * | 2022-05-25 | 2023-11-30 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
| KR20250105657A (ko) * | 2022-11-15 | 2025-07-08 | 아스트라제네카 아베 | 카피바설팁과 베네토클락스의 치료적 조합 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2201012T3 (pl) | 2007-10-11 | 2014-11-28 | Astrazeneca Ab | Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b |
| EP3689878B1 (en) | 2011-07-19 | 2021-10-06 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors |
| KR20160090903A (ko) * | 2013-12-04 | 2016-08-01 | 길리애드 사이언시즈, 인코포레이티드 | 암을 치료하는 방법 |
| CN105979948A (zh) * | 2013-12-05 | 2016-09-28 | 安塞塔制药公司 | Pi3k抑制剂和btk抑制剂的治疗组合 |
| US20180353512A1 (en) * | 2015-06-23 | 2018-12-13 | Gilead Sciences, Inc. | Combination therapies for treating b-cell malignancies |
| US20170071962A1 (en) * | 2015-09-11 | 2017-03-16 | Acerta Pharma B.V. | Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor |
| CU20180059A7 (es) * | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| CN107344940B (zh) * | 2016-05-06 | 2020-04-21 | 广东东阳光药业有限公司 | Btk抑制剂及其用途 |
| WO2018097977A1 (en) * | 2016-11-22 | 2018-05-31 | Gilead Sciences, Inc. | Crystalline forms of a phosphate complex of a bet inhibitor |
| WO2019058348A1 (en) * | 2017-09-25 | 2019-03-28 | Astrazeneca Ab | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
-
2020
- 2020-10-30 EP EP20800617.1A patent/EP4054582B1/en active Active
- 2020-10-30 MX MX2022005250A patent/MX2022005250A/es unknown
- 2020-10-30 PT PT208006171T patent/PT4054582T/pt unknown
- 2020-10-30 FI FIEP20800617.1T patent/FI4054582T3/fi active
- 2020-10-30 DK DK20800617.1T patent/DK4054582T3/da active
- 2020-10-30 WO PCT/EP2020/080493 patent/WO2021089419A1/en not_active Ceased
- 2020-10-30 US US17/755,548 patent/US20220401442A1/en active Pending
- 2020-10-30 KR KR1020227018891A patent/KR20220098175A/ko active Pending
- 2020-10-30 JP JP2022525916A patent/JP7575454B2/ja active Active
- 2020-10-30 ES ES20800617T patent/ES3055126T3/es active Active
- 2020-10-30 CN CN202080076132.6A patent/CN114728003B/zh active Active
- 2020-10-30 AU AU2020381240A patent/AU2020381240C1/en active Active
- 2020-10-30 PL PL20800617.1T patent/PL4054582T3/pl unknown
- 2020-10-30 CA CA3158321A patent/CA3158321A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114728003B (zh) | 2025-01-28 |
| DK4054582T3 (da) | 2025-12-01 |
| US20220401442A1 (en) | 2022-12-22 |
| WO2021089419A1 (en) | 2021-05-14 |
| ES3055126T3 (en) | 2026-02-10 |
| PL4054582T3 (pl) | 2026-02-16 |
| JP7575454B2 (ja) | 2024-10-29 |
| JP2023501317A (ja) | 2023-01-18 |
| EP4054582B1 (en) | 2025-09-03 |
| PT4054582T (pt) | 2025-12-10 |
| CN114728003A (zh) | 2022-07-08 |
| EP4054582A1 (en) | 2022-09-14 |
| FI4054582T3 (fi) | 2025-12-04 |
| AU2020381240B2 (en) | 2023-09-07 |
| AU2020381240A1 (en) | 2022-06-23 |
| AU2020381240C1 (en) | 2024-02-15 |
| MX2022005250A (es) | 2022-06-08 |
| KR20220098175A (ko) | 2022-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6742391B2 (ja) | 併用療法 | |
| TWI607754B (zh) | 醫藥組合 | |
| JP6911047B2 (ja) | がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法 | |
| JP2024516363A (ja) | リボシクリブ及びアムセネストラントを含む組み合わせ | |
| CN114246864B (zh) | Csf1r激酶抑制剂及其用途 | |
| JP6860949B2 (ja) | 癌の処置方法 | |
| JP2022514056A (ja) | 癌の治療に使用するためのＲａｆ阻害剤及びＣＤＫ４／６阻害剤による組み合わせ療法 | |
| JP7703124B1 (ja) | Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法 | |
| AU2020381240C1 (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies | |
| EA045670B1 (ru) | Терапевтические комбинации акалабрутиниба и капивасертиба для лечения в-клеточных злокачественных образований | |
| HK40069821B (zh) | 治疗b细胞恶性肿瘤的阿卡替尼和卡帕塞替尼的治疗组合 | |
| HK40069821A (en) | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies | |
| WO2026076264A1 (en) | Treatment of lymphomas using an ezh2 inhibitor | |
| HK40051622A (en) | Combination therapy comprising a b-raf inhibitor and a second inhibitor | |
| TW202508598A (zh) | 癌症療法 | |
| WO2023038030A1 (ja) | 固形腫瘍治療用医薬組成物 | |
| EA040191B1 (ru) | Комбинированная терапия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240826 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20240826 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241016 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250331 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250708 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250925 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251120 |